Article info
PDFTherapeutics
Randomised controlled trial
For people with non-valvular atrial fibrillation rivaroxaban is non-inferior to warfarin for preventing stroke or embolism, with no difference in the risk of clinically relevant bleeding
- Correspondence to Matthew Sherwood
Duke Clinical Research Institute, Duke University Medical Center, PO Box 17969, Durham, NC 27710, USA; matthew.sherwood{at}duke.edu
Citation
For people with non-valvular atrial fibrillation rivaroxaban is non-inferior to warfarin for preventing stroke or embolism, with no difference in the risk of clinically relevant bleeding
Publication history
- First published February 18, 2012.
Online issue publication
July 27, 2020
Article Versions
- Previous version (27 July 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions